Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus pemetrexed and carboplatin as first-line therapy for malignant pleural mesothelioma
2006-004429-27Phase 2Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, pemetrexed and carboplatin in pleural mesothelioma, sponsored by Humanitas Research Hospital. Primary endpoint: Median progression-free survival. Started Oct 2007; status: completed.
02
Drugs
bevacizumabpemetrexedcarboplatin
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2006-004429-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004429-27.